Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Stivarga (regorafenib)
i
Other names:
BAY 73-4506, BAY-734506, BAY 734506, BAY734506
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(65)
News
Trials
Company:
Amgen, Bayer
Drug class:
Multi-tyrosine kinase inhibitor
Related drugs:
‹
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
sorafenib (180)
anlotinib (139)
ponatinib (98)
pazopanib (76)
gilteritinib (75)
cabozantinib tablet (74)
midostaurin (51)
repotrectinib (27)
vandetanib (26)
cabozantinib capsule (24)
nintedanib (18)
TT-00420 (16)
SHR 1020 (5)
MGCD516 (5)
AEE788 (4)
APG-2449 (4)
donafenib (2)
AMG 706 (2)
HA121-28 (1)
SY-707 (1)
CT053PTSA (1)
sorafenib nanoparticle (0)
masitinib (0)
TSN084 (0)
TAS-115 (0)
›
Associations
(65)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Gastrointestinal Stromal Tumor
No biomarker
Gastrointestinal Stromal Tumor
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Colorectal Cancer
No biomarker
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
RAS wild-type
Colorectal Cancer
RAS wild-type
Colorectal Cancer
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
regorafenib
Sensitive: A1 - Approval
regorafenib
Sensitive
:
A1
No biomarker
Osteosarcoma
No biomarker
Osteosarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Glioblastoma
No biomarker
Glioblastoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Rectal Cancer
No biomarker
Rectal Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
SDHB deletion
Gastrointestinal Stromal Tumor
SDHB deletion
Gastrointestinal Stromal Tumor
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Colon Cancer
No biomarker
Colon Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
No biomarker
Ewing Sarcoma
No biomarker
Ewing Sarcoma
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
regorafenib
Sensitive: A2 - Guideline
regorafenib
Sensitive
:
A2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.